12:00 AM
Jan 29, 2007
 |  BioCentury  |  Tools & Techniques

Unmasking gp120

Although more than 50 different preventive HIV vaccine candidates have entered clinical trials since 1987, none has been approved. A newly discovered region of HIV gp120 could revive interest in what was one of the original vaccine targets, because it is exposed, semi-conserved and highly sensitive to monoclonal antibodies.

"Previous vaccines have used one or two gp120 sequences," said Abraham Pinter, head of the laboratory of retroviral biology at the...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >